Form D · Pharmaceuticals
RedHill Biopharma Ltd.
Tel Aviv, L3 · CIK 0001553846
Offering snapshot reported Feb 5, 2024 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 25, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 5, 2024 | Initial | $10,000,000 | No comparison | 5 | SEC filing |
| Oct 12, 2023 | Initial | $4,043,808 | No comparison | 3 | SEC filing |
| Aug 7, 2023 | Initial | $2,700,000 | No comparison | 1 | SEC filing |
| Nov 22, 2021 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Nov 6, 2019 | Initial | $48,300,000 | No comparison | 2 | SEC filing |
| Jan 15, 2014 | Initial | $2,500,020 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $600K
- Finders' fees
- $0
- Form D file number
- 021-504349
This Form D is being filed in connection with the issuance of warrants to purchase up to 10,000,000 American Depositary Shares ("ADSs") at an exercise price of $1.00 per ADS, each ADS representing 400 ordinary shares, par value NIS 0.01, of the Company
The placement agent (or its designees) also received warrants to purchase up to 600,000 ADSs of the Company, at an exercise price of $1.00 per ADS under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Feb 5, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| June Almenoff | Executive |
| Dror Ben Asher | Director, Executive |
| Micha Ben Chorin | Executive |
| Shmuel Cabilly | Director |
| Reza Fathi | Executive |
| Alla Felder | Director |
| Adi Frish | Executive |
| Guy Goldberg | Executive |
| Uri Hananel Aharon | Executive |
| Razi Ingber | Executive |
| Gilead Raday | Executive |
| Kenneth Reed | Director |
| Aliza Rotbard | Director |
| Rick Scruggs | Director, Executive |
| Ori Shilo | Director, Executive |
| Dan Suesskind | Director |
| Eric Swenden | Director |
| Ofer Tsimchi | Director |
| Nicolas Weinstein | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
21 Ha'arba'a Street
Tel Aviv, L3, 6473921
Tel Aviv, L3, 6473921